| Comprehensive molecular characterization of urothelial bladder carcinoma Cancer Genome Atlas Research Network Nature 507 (7492), 315, 2014 | 2948 | 2014 |
| Delivery of siRNA therapeutics: barriers and carriers J Wang, Z Lu, MG Wientjes, JLS Au The AAPS journal 12 (4), 492-503, 2010 | 1020 | 2010 |
| Drug delivery and transport to solid tumors SH Jang, MG Wientjes, D Lu, JLS Au Pharmaceutical research 20 (9), 1337-1350, 2003 | 686 | 2003 |
| MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer G Hu, RA Chong, Q Yang, Y Wei, MA Blanco, F Li, M Reiss, JLS Au, ... Cancer cell 15 (1), 9-20, 2009 | 531 | 2009 |
| Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses L Zhao, MG Wientjes, JLS Au Clinical cancer research 10 (23), 7994-8004, 2004 | 485 | 2004 |
| Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial JLS Au, RA Badalament, MG Wientjes, DC Young, JA Warner, ... Journal of the National Cancer Institute 93 (8), 597-604, 2001 | 439 | 2001 |
| Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy Z Lu, TK Yeh, M Tsai, JLS Au, MG Wientjes Clinical Cancer Research 10 (22), 7677-7684, 2004 | 338 | 2004 |
| Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor Y Li, J Wang, MG Wientjes, JLS Au Advanced drug delivery reviews 64 (1), 29-39, 2012 | 273 | 2012 |
| Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs SH Song, MG Wientjes, Y Gan, JLS Au Proceedings of the National Academy of Sciences 97 (15), 8658-8663, 2000 | 267 | 2000 |
| Comparison of methods for evaluating drug-drug interaction L Zhao, JLS Au, MG Wientjes Frontiers in bioscience (Elite edition) 2, 241, 2010 | 257 | 2010 |
| The heparanase/syndecan‐1 axis in cancer: mechanisms and therapies VC Ramani, A Purushothaman, MD Stewart, CA Thompson, I Vlodavsky, ... The FEBS journal 280 (10), 2294-2306, 2013 | 226 | 2013 |
| Determinants of drug delivery and transport to solid tumors JLS Au, SH Jang, J Zheng, CT Chen, S Song, L Hu, MG Wientjes Journal of controlled release 74 (1-3), 31-46, 2001 | 226 | 2001 |
| Intravesical treatments of bladder cancer Z Shen, T Shen, MG Wientjes, MA O’Donnell, JLS Au Pharmaceutical research 25 (7), 1500-1510, 2008 | 224 | 2008 |
| Determinants of paclitaxel penetration and accumulation in human solid tumor HJ Kuh, SH Jang, MG Wientjes, JR Weaver, JLS Au The Journal of pharmacology and experimental therapeutics 290 (2), 871-880, 1999 | 221 | 1999 |
| Intraperitoneal therapy for peritoneal cancer Z Lu, J Wang, MG Wientjes, JLS Au Future oncology 6 (10), 1625-1641, 2010 | 208 | 2010 |
| Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities JLS Au, BZ Yeung, MG Wientjes, Z Lu, MG Wientjes Advanced drug delivery reviews 97, 280-301, 2016 | 178 | 2016 |
| Protection against chemotherapy-induced alopecia J Wang, Z Lu, JLS Au Pharmaceutical research 23 (11), 2505-2514, 2006 | 172 | 2006 |
| Kinetics of P-glycoprotein-mediated efflux of paclitaxel SH Jang, MG Wientjes, JLS Au The Journal of pharmacology and experimental therapeutics 298 (3), 1236-1242, 2001 | 167 | 2001 |
| Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel M Tsai, Z Lu, J Wang, TK Yeh, MG Wientjes, JLS Au Pharmaceutical research 24 (9), 1691-1701, 2007 | 166 | 2007 |
| Tumor priming enhances delivery and efficacy of nanomedicines D Lu, MG Wientjes, Z Lu, JLS Au The Journal of pharmacology and experimental therapeutics 322 (1), 80-88, 2007 | 155 | 2007 |
